Gaurav Shah

All filings by Gaurav Shah on record concern Rocket Pharmaceuticals, Inc., in the capacity of chief executive. The record holds 26 filings, for trades running from 7 February 2022 to 18 August 2026.

In open-market terms, that means 2 purchases worth €423k on one side and 15 sales worth €1.5M on the other. The net balance comes to €1.1M on the selling side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 3 share grants and 6 option exercises. 2026 to date brings no purchases and 5 sales.

The latest filing, published on 20 August 2026, reports an open-market sale of €6,691 in Rocket Pharmaceuticals, Inc. The latest purchase dates back some time: it was published 552 days ago, on 14 April 2025. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.